Leap Therapeutics, Inc. (LPTX)

US — Healthcare Sector
Peers: XFOR  TERN  DAWN  PDSB  INZY  EFTR  ELEV  MREO  HEPA  HOOK  ABOS 

Automate Your Wheel Strategy on LPTX

With Tiblio's Option Bot, you can configure your own wheel strategy including LPTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol LPTX
  • Rev/Share 0.0
  • Book/Share 0.505
  • PB 0.7485
  • Debt/Equity 0.0074
  • CurrentRatio 2.4126
  • ROIC -3.4179

 

  • MktCap 15664131.0
  • FreeCF/Share -1.436
  • PFCF -0.2643
  • PE -0.2255
  • Debt/Assets 0.0044
  • DivYield 0
  • ROE -1.6215

 

  • Rating B
  • Score 3
  • Recommendation Neutral
  • P/E Score 1
  • DCF Score 5
  • P/B Score 4
  • D/E Score 4

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Downgrade LPTX H.C. Wainwright Buy Neutral -- -- Jan. 29, 2025
Downgrade LPTX Robert W. Baird Outperform Neutral $9 $1.25 Jan. 29, 2025

News

Leap Therapeutics to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, at the AACR 2025 Annual Meeting
LPTX
Published: April 25, 2025 by: PRNewsWire
Sentiment: Neutral

FL-501 fully restored body composition and reversed key indicators of cachexia in preclinical models Findings confirm GDF-15's role in cachexia and support advancing FL-501 into the clinic CAMBRIDGE, Mass. , April 25, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced it will present preclinical data of FL-501 in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting taking place April 25-30 in Chicago, Illinois.

Read More
image for news Leap Therapeutics to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, at the AACR 2025 Annual Meeting
Leap Therapeutics (LPTX) Conference Call to discuss Updated Data from Part B of the DeFianCe Study Transcript
LPTX
Published: March 31, 2025 by: Seeking Alpha
Sentiment: Neutral

Leap Therapeutics (NASDAQ:LPTX ) Conference Call to discuss Updated Data from Part B of the DeFianCe Study March 26, 2025 8:00 AM ET Company Participants Douglas Onsi - President and CEO Cyndi Sirard - Chief Medical Officer Jason Baum - Chief Scientific Officer Conference Call Participants Matthew Pipps - William Blair Swayampakula Ramakanth - H.C. Wainwright Operator Good morning.

Read More
image for news Leap Therapeutics (LPTX) Conference Call to discuss Updated Data from Part B of the DeFianCe Study Transcript
Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer
LPTX
Published: March 26, 2025 by: Benzinga
Sentiment: Positive

Leap Therapeutics, Inc. LPTX presented updated preliminary data on Wednesday from Part B of the DeFianCe Phase 2 trial of sirexatamab (DKN-01) in combination with bevacizumab and chemotherapy (Experimental Arm) compared to bevacizumab and chemotherapy (Control Arm).

Read More
image for news Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer
Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study
LPTX
Published: March 26, 2025 by: PRNewsWire
Sentiment: Neutral

Updated data confirms statistically significant 32% higher ORR and 3.5 month longer PFS in second-line CRC patients with high DKK1 levels treated with sirexatamab plus bevacizumab and chemotherapy Statistically significant 22% higher ORR and 2.6 month longer PFS in patients who had not had prior anti-VEGF therapy Leap to host a conference call to present clinical data today, March 26, 2025, at 8:00 a.m. ET CAMBRIDGE, Mass.

Read More
image for news Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study

About Leap Therapeutics, Inc. (LPTX)

  • IPO Date 2017-01-25
  • Website https://www.leaptx.com
  • Industry Biotechnology
  • CEO Mr. Douglas E. Onsi J.D.
  • Employees 52

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.